Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

110194 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ABACAVIR AND LAMIVUDINE ZIDOVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE LAMIVUDINE ORAL ABACAVIR , LAMIVUDINE AND ZIDOVUDINE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 20138
1 CHRONIC KIDNEY DISEASE 12670
2 RENAL FAILURE 11187
3 OSTEONECROSIS 10776
4 BONE LOSS 10599
5 TOOTH LOSS 9915
6 MULTIPLE FRACTURES 9566
7 PAIN 9205
8 OSTEOPOROSIS 9054
9 RENAL INJURY 9017
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BONE DEMINERALISATION 846 0.7989
1 SKELETAL INJURY 7941 0.7671
2 BONE LOSS 10599 0.7043
3 BONE DENSITY DECREASED 20138 0.6421
4 MULTIPLE FRACTURES 9566 0.5817
5 IMMUNE RECONSTITUTION SYNDROME 733 0.5678
6 VIRAL MUTATION IDENTIFIED 2065 0.5601
7 BLOOD HIV RNA INCREASED 946 0.5212
8 TOOTH INJURY 2106 0.4846
9 VIROLOGIC FAILURE 2594 0.4819
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]